University of Wisconsin Hematology

COVID

  1. Iba et al. Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned? J Thromb Haemost 2024;22:1541
  2. Thomas and Scully. Clinical features of thrombosis and bleeding in COVID-19. Blood 2022;140:184
  3. Re et al. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients. JAMA 2022;328:637 (Slightly higher rate of venous thrombosis, not arterial thrombosis with COVID)
  4. Baumann Kreuziger et al. Anticoagulation in hospitalized patients with COVID-19. Blood 2022; 140:809
  5. Schulman et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2022;20:2214
  6. Schulman et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2024;22:1779
  7. Leentjens et al COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year. Lancet Haematol 2021;8:e524
  8. Cuker et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv 2022;6:664
  9. Ramacciotti et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022;399:50 (Thrombosis incidence 3% with rivaroxaban 10 mg/d, 9% without; no major bleeding in this cohort of high-risk patients) 
  10. Thachil et al. ISTH DIC subcommittee communication on anticoagulation in COVID‐19. J Thromb Haemost 2020;18:2138
  11. Iba et al. Proposal of the Definition for COVID-19-Associated Coagulopathy. J Clin Med 2021;10:191
  12. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM 2021;385:777(No benefit)
  13. The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM 2021;385:790(Therapeutic heparin increased organ support-free days)
  14. INSPIRATION Investgators. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. The INSPIRATION Randomized Clinical Trial. JAMA 2021;325:1620(No benefit to intermediate-dose enoxaparin vs prophylactic dose)
  15. Spyropoulos et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021;181:1612 (“Thromboprophylaxis with therapeutic-dose low-molecular-weight heparin reduces a composite outcome of major thromboembolism and death in high-risk inpatients with COVID-19”)
  16. Labbé et al. Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. The ANTICOVID Randomized Clinical Trial. JAMA Intern Med 2023;183:520 (High-dose prophylaxis with LMWH gave better outcomes in a population with low bleeding risk)
  17. Goligher et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA 2023;329:1066 (Heparin beneficial in less severely ill patients and those with lower BMIs)
  18. Swan et al. Heparin – Messias or Verschlimmbesserung? J Thromb Haemost 2021;19:2373(Heparin resistance in COVID infection)
  19. Tang et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094(With commentary)
  20. Lopes et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021;397:2253(No benefit from therapeutic as opposed to prophylactic anticoagulation)
  21. Tang et al Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844
  22. Yan et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China. A retrospective study. Chinese Med J 2020 (Epub)
  23. Thachil et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost 2019;18:1023
  24. Hunt and Levi. The source of elevated plasma D-dimer levels in COVID-19 infection. Br JHaematol 2020 (Epub)(Proposes that lysis of intra-alveolar fibrin rather than DIC is the main source of D-dimer)
  25. Zhang et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. J Thromb Haemost 2020;18:1324
  26. Panigada et al. Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18:1738(Results more consistent with hypercoagulability than DIC)
  27. Al-Samkari et al. COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. Blood 2020;136:489
  28. Connors and Levy. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033
  29. Nicolai et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. Circulation 2020;142:1176
  30. Busch et al. Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19. Circulation 2020;142:1787
  31. Levi et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7:e438
  32. Helms et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intens Care Med 2020;46:1089
  33. Llitjos et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost 2020;18:1743(Retrospective study showing high rates of VTE in patients with severe COVID infection, even in therapeutically anticoagulated patients)
  34. Xie et al. Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. JAMA Intern Med 2022;182:1063
  35. Jara-Palomares et al. Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19–Associated Venous Thromboembolism. JAMA Intern Med 2022;182:1326 (Low recurrence rate supports limited course of anticoagulation)
  36. Gavriilaki and Brodsky. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol 2020;169:e227
  37. Yu et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020;136:2080
  38. Levi and Hunt. Thrombosis and coagulopathy in COVID‐19: An illustrated review. Res Pract Thromb Haemost 2020; 4:744
  39. Bowles et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. NEJM 2020;383:288(91% of hospitalized COVID pts with long aPTT had LAC)
  40. Ackermann et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. NEJM 2020;383:120(Autopsy study)
  41. Spyropoulos et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020;18:1859
  42. Middeldorp et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020;18:1995(13% incidence of symptomatic VTE despite routine prophylaxis)
  43. Muñoz-Rivas et al. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study. Thromb Res 2021;199:132(6% incidence of arterial or venous thrombosis despite LMWH prophylaxis)
  44. Whyte et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19. J Thromb Haemost 2020;18:1548(Suggests nebulized tPA as treatment to lyse intra-alveolar fibrin)
  45. Nougier et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis. J Thromb Haemost 2020;18:2215
  46. Testa et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost 2020;18:1320(Suggests not to use DOACs in COVID patients on antivirals)
  47. Hegerova et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood 2020;136:759
  48. Xia et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020;136:755(50% lower mortality in plasma-treated patients)
  49. Middleton et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020;136:1169
  50. Hottz et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19, Blood 2020;136:1330
  51. Patell et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020;136:1342(2.5% incidence of thrombosis, 3.7% incidence of bleeding in non-anticoagulated pts by day 30 post discharge)
  52. Santoliquido et al. Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis. J Thromb Haemost 2020;18:2358 (12% incidence of DVT, mostly distal)
  53. Pesavento et al. The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience. J Thromb Haemost 2020;18:2629(Retrospectivee study: no benefit to higher doses of anticoagulants vs prophylactic dose)
  54. Lachant et al. Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection. J Thromb Haemost 2020;18:2640(Retrospective study, uncontrolled; no thrombotic complications, 3% rate of minor bleeding)
  55. Wood et al. How should we use convalescent plasma therapies for the management of COVID-19? Blood 2021;137:1573
  56. Fajgenbaum and June. Cytokine storm. NEJM 2020;383:2255
  57. Giannis et al Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 2021;137:2838(90-day postdischarge VTE and arterial thrombosis rates in 1-2% range; prophylactic anticoagulant use associated with 46% decrease in mortality)
  58. Connors et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19.  The ACTIV-4B Randomized Clinical Trial. JAMA 2021;:326:1703 (Neither aspirin or apixaban of benefit; event rates low)
  59. Krinsky et al. NETosis induction reflects COVID-19 severity and long COVID: insights from a 2-center patient cohort study in Israel. J Thromb Haemost 2023;21:2569
  60. Nicolai et al. Thromboinflammation in long COVID—the elusive key to postinfection sequelae? J Thromb Haemost 2023;21:2020
  61. Taquet et al. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med 2023 (Epub) (High fibrinogen or D-dimer/CRP ratio associated with long COVID cognitive problems)
  62. Klang et al. Most impactful COVID-19 articles in the field of thrombosis and hemostasis literature. J Thromb Haemost 2022;20:2700